New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 23, 2014
07:38 EDTLPTNLpath's Lpathomab to be studied for efficacy in traumatic brain injury
Lpath and scientists from the Center for Military Psychiatry and Neuroscience, Walter Reed Army Institute of Research, have initiated a study that is the focus of a collaborative research agreement involving the use of Lpathomab, an antibody to lysophosphatidic acid, in the treatment of brain injury induced by blast overpressure. There are currently no FDA-approved drug treatments for any form of TBI. Lpath is currently conducting IND-enabling studies for Lpathomab and intends to enter Phase 1 clinical trials in early 2015 for neuropathic pain and neurotrauma.
News For LPTN From The Last 14 Days
Check below for free stories on LPTN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for LPTN

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use